Phase 3 Rare Disease Deal Benchmarks

Phase 3 rare disease licensing deals carry a median total deal value of $3.4B, with upfront payments ranging from $583M to $1.3B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 29% to upfront and 71% to milestones.

The rare disease landscape at the phase 3 stage is characterized by limited competitive intensity per indication but growing platform competition. Development milestones average $239M, regulatory milestones contribute $478M, and commercial milestones reach $1.7B. Gene therapies and oligonucleotide-based approaches are transforming treatment paradigms, with orphan designations enabling premium pricing and accelerated regulatory paths.